Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis

Por Schmid, Ulrike, Liesenfeld, Karl-Heinz, Fleury, Angele, Dallinger, Claudia, Freiwald, Matthias
Publicado no Cancer Chemother Pharmacol (2017)

Pharmacometric Characterization of Dabigatran Hemodialysis

Por Liesenfeld, Karl-Heinz, Staab, Alexander, Härtter, Sebastian, Formella, Stephan, Clemens, Andreas, Lehr, Thorsten
Publicado em 2013

Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic simi...

Por Kang, Jia, Eudy‐Byrne, Rena J., Mondick, John, Knebel, William, Jayadeva, Girish, Liesenfeld, Karl‐Heinz
Publicado no Br J Clin Pharmacol (2020)

Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis

Por Liesenfeld, Karl-Heinz, Schäfer, Hans G, Trocóniz, Iñaki F, Tillmann, Christiane, Eriksson, Bengt I, Stangier, Joachim
Publicado em 2006

Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled...

Por Moschetti, Viktoria, Desch, Michael, Goetz, Sophia, Liesenfeld, Karl-Heinz, Rosenbrock, Holger, Kammerer, Klaus-Peter, Wunderlich, Glen, Wind, Sven
Publicado no Eur J Drug Metab Pharmacokinet (2017)

Multiple Rising Doses of Oral BI 425809, a GlyT1 Inhibitor, in Young and Elderly Healthy Volunteers: A Randomised, Double-Blind, Phase I Study Investigating Safety and Pharmacokine...

Por Moschetti, Viktoria, Schlecker, Christina, Wind, Sven, Goetz, Sophia, Schmitt, Holger, Schultz, Armin, Liesenfeld, Karl-Heinz, Wunderlich, Glen, Desch, Michael
Publicado no Clin Drug Investig (2018)

Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder

Por Tsuda, Yasuhiro, Tatami, Shinji, Yamamura, Norio, Tadayasu, Yusuke, Sarashina, Akiko, Liesenfeld, Karl-Heinz, Staab, Alexander, Schäfer, Hans-Günter, Ieiri, Ichiro, Higuchi, Shun
Publicado em 2010

Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies

Por Rosenbrock, Holger, Desch, Michael, Kleiner, Oliver, Dorner‐Ciossek, Cornelia, Schmid, Bernhard, Keller, Sascha, Schlecker, Christina, Moschetti, Viktoria, Goetz, Sophia, Liesenfeld, Karl‐Heinz, Fillon, Gwenaelle, Giovannini, Riccardo, Ramael, Steven, Wunderlich, Glen, Wind, Sven
Publicado no Clin Transl Sci (2018)

Low‐dose empagliflozin as adjunct‐to‐insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacy

Por Perkins, Bruce A., Soleymanlou, Nima, Rosenstock, Julio, Skyler, Jay S., Laffel, Lori M., Liesenfeld, Karl‐Heinz, Neubacher, Dietmar, Riggs, Matthew M., Johnston, Curtis K., Eudy‐Byrne, Rena J., Elmokadem, Ahmed, George, Jyothis T., Marquard, Jan, Nock, Valerie
Publicado no Diabetes Obes Metab (2020)